futuragene limited
futuragene limited Company Information
Company Number
04001406
Next Accounts
Sep 2025
Shareholders
suzano sa
Group Structure
View All
Industry
Research and experimental development on biotechnology
Registered Address
45 45 gresham strret, london, EC2V 7BG
Website
www.futuragene.comfuturagene limited Estimated Valuation
Pomanda estimates the enterprise value of FUTURAGENE LIMITED at £0 based on a Turnover of £0 and 1.35x industry multiple (adjusted for size and gross margin).
futuragene limited Estimated Valuation
Pomanda estimates the enterprise value of FUTURAGENE LIMITED at £0 based on an EBITDA of £-5.7m and a 5.31x industry multiple (adjusted for size and gross margin).
futuragene limited Estimated Valuation
Pomanda estimates the enterprise value of FUTURAGENE LIMITED at £5.3m based on Net Assets of £3m and 1.79x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Futuragene Limited Overview
Futuragene Limited is a live company located in london, EC2V 7BG with a Companies House number of 04001406. It operates in the research and experimental development on biotechnology sector, SIC Code 72110. Founded in May 2000, it's largest shareholder is suzano sa with a 100% stake. Futuragene Limited is a mature, unknown sized company, Pomanda has estimated its turnover at £0 with unknown growth in recent years.
Upgrade for unlimited company reports & a free credit check
Futuragene Limited Health Check
Pomanda's financial health check has awarded Futuragene Limited a 2.5 rating. We use a traffic light system to show it exceeds the industry average on 2 measures and has 1 areas for improvement. Company Health Check FAQs
2 Strong
1 Regular
1 Weak
Size
There is insufficient data available for this Key Performance Indicator!
- - Futuragene Limited
- - Industry AVG
Growth
There is insufficient data available for this Key Performance Indicator!
- Futuragene Limited
- - Industry AVG
Production
There is insufficient data available for this Key Performance Indicator!
- - Futuragene Limited
- - Industry AVG
Profitability
There is insufficient data available for this Key Performance Indicator!
- - Futuragene Limited
- - Industry AVG
Employees
with 1 employees, this is below the industry average (54)
- Futuragene Limited
- - Industry AVG
Pay Structure
on an average salary of £83.2k, the company has an equivalent pay structure (£83.2k)
- Futuragene Limited
- - Industry AVG
Efficiency
There is insufficient data available for this Key Performance Indicator!
- Futuragene Limited
- - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- - Futuragene Limited
- - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- - Futuragene Limited
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Futuragene Limited
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 747 weeks, this is more cash available to meet short term requirements (30 weeks)
- - Futuragene Limited
- - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 6.9%, this is a lower level of debt than the average (52.5%)
- - Futuragene Limited
- - Industry AVG
FUTURAGENE LIMITED financials
Futuragene Limited's latest turnover from December 2023 is 0 and the company has net assets of £3 million. According to their latest financial statements, we estimate that Futuragene Limited has 1 employee and maintains cash reserves of £3.2 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 49,000 | 58,000 | 175,000 | 165,000 | 91,000 | 32,000 | 116,000 | 181,000 | |||||||
| Other Income Or Grants | |||||||||||||||
| Cost Of Sales | |||||||||||||||
| Gross Profit | 49,000 | ||||||||||||||
| Admin Expenses | 1,090,000 | ||||||||||||||
| Operating Profit | -5,738,183 | -9,366,943 | -4,064,000 | -8,401,000 | -11,403,000 | -15,037,000 | -2,210,000 | -1,041,000 | -7,334,000 | -6,791,000 | -9,487,000 | -11,129,000 | -5,614,000 | -5,008,000 | -3,703,000 |
| Interest Payable | 231,000 | 122,000 | 15,000 | 88,000 | |||||||||||
| Interest Receivable | 37,000 | 53,000 | 36,000 | 19,000 | 755,000 | 598,000 | 262,000 | 262,000 | 25,000 | 3,000 | 8,000 | 1,000 | |||
| Pre-Tax Profit | -5,738,183 | -9,366,943 | -4,976,000 | -8,913,000 | -13,315,000 | -12,192,000 | -6,407,000 | -517,000 | -6,858,000 | -6,544,000 | -9,313,000 | -11,104,000 | -5,611,000 | -5,000,000 | -3,702,000 |
| Tax | -40,000 | -41,000 | |||||||||||||
| Profit After Tax | -5,738,183 | -9,366,943 | -4,976,000 | -8,913,000 | -13,315,000 | -12,192,000 | -6,407,000 | -557,000 | -6,899,000 | -6,544,000 | -9,313,000 | -11,104,000 | -5,611,000 | -5,000,000 | -3,702,000 |
| Dividends Paid | |||||||||||||||
| Retained Profit | -5,738,183 | -9,366,943 | -4,976,000 | -8,913,000 | -13,315,000 | -12,192,000 | -6,407,000 | -557,000 | -6,899,000 | -6,544,000 | -9,313,000 | -11,104,000 | -5,611,000 | -5,000,000 | -3,702,000 |
| Employee Costs | 4,037,000 | 3,954,000 | 3,675,000 | 3,901,000 | 4,561,000 | 2,698,000 | 1,799,000 | 1,380,000 | |||||||
| Number Of Employees | 122 | 117 | 102 | 95 | 96 | 62 | 29 | 24 | |||||||
| EBITDA* | -5,738,183 | -9,366,943 | -4,064,000 | -8,401,000 | -11,403,000 | -15,037,000 | -2,210,000 | -675,000 | -7,045,000 | -6,487,000 | -9,167,000 | -10,899,000 | -5,516,000 | -4,978,000 | -3,672,000 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 3,289,000 | 2,345,000 | 2,540,000 | 2,261,000 | 2,274,000 | 2,007,000 | 173,000 | 149,000 | |||||||
| Intangible Assets | |||||||||||||||
| Investments & Other | |||||||||||||||
| Debtors (Due After 1 year) | |||||||||||||||
| Total Fixed Assets | 3,289,000 | 2,345,000 | 2,540,000 | 2,261,000 | 2,274,000 | 2,007,000 | 173,000 | 149,000 | |||||||
| Stock & work in progress | 246,000 | ||||||||||||||
| Trade Debtors | 80,000 | ||||||||||||||
| Group Debtors | |||||||||||||||
| Misc Debtors | 8,440 | 3,000 | 2,000 | 3,000 | 936,000 | 825,000 | 648,000 | 350,000 | 332,000 | 287,000 | 190,000 | 450,000 | |||
| Cash | 3,189,840 | 2,382,596 | 3,766,000 | 2,845,000 | 758,000 | 478,000 | 83,000 | 11,129,000 | 7,595,000 | 6,854,000 | 7,747,000 | 5,313,000 | 3,465,000 | 2,466,000 | 2,803,000 |
| misc current assets | |||||||||||||||
| total current assets | 3,198,281 | 2,382,597 | 3,766,000 | 2,848,000 | 760,000 | 481,000 | 83,000 | 12,311,000 | 8,420,000 | 7,582,000 | 8,097,000 | 5,645,000 | 3,752,000 | 2,656,000 | 3,253,000 |
| total assets | 3,198,281 | 2,382,597 | 3,766,000 | 2,848,000 | 760,000 | 481,000 | 83,000 | 15,600,000 | 10,765,000 | 10,122,000 | 10,358,000 | 7,919,000 | 5,759,000 | 2,829,000 | 3,402,000 |
| Bank overdraft | |||||||||||||||
| Bank loan | 12,000 | 6,000 | |||||||||||||
| Trade Creditors | 404,000 | 254,000 | 235,000 | 313,000 | 377,000 | 385,000 | 197,000 | 105,000 | |||||||
| Group/Directors Accounts | |||||||||||||||
| other short term finances | |||||||||||||||
| hp & lease commitments | |||||||||||||||
| other current liabilities | 221,761 | 191,068 | 86,000 | 135,000 | 29,000 | 907,000 | 85,000 | 1,598,000 | 859,000 | 1,226,000 | 4,196,000 | 4,463,000 | 5,232,000 | 3,543,000 | 743,000 |
| total current liabilities | 221,762 | 191,068 | 86,000 | 135,000 | 29,000 | 907,000 | 85,000 | 2,014,000 | 1,119,000 | 1,461,000 | 4,509,000 | 4,840,000 | 5,617,000 | 3,740,000 | 848,000 |
| loans | 13,996,000 | 6,392,000 | |||||||||||||
| hp & lease commitments | |||||||||||||||
| Accruals and Deferred Income | |||||||||||||||
| other liabilities | 262,000 | ||||||||||||||
| provisions | |||||||||||||||
| total long term liabilities | 6,998,000 | 3,458,000 | |||||||||||||
| total liabilities | 221,762 | 191,068 | 86,000 | 135,000 | 29,000 | 907,000 | 85,000 | 9,012,000 | 4,577,000 | 1,461,000 | 4,509,000 | 4,840,000 | 5,617,000 | 3,740,000 | 848,000 |
| net assets | 2,976,519 | 2,191,529 | 3,680,000 | 2,713,000 | 731,000 | -426,000 | -2,000 | 6,588,000 | 6,188,000 | 8,661,000 | 5,849,000 | 3,079,000 | 142,000 | -911,000 | 2,554,000 |
| total shareholders funds | 2,976,519 | 2,191,529 | 3,680,000 | 2,713,000 | 731,000 | -426,000 | -2,000 | 6,588,000 | 6,188,000 | 8,661,000 | 5,849,000 | 3,079,000 | 142,000 | -911,000 | 2,554,000 |
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||
| Operating Profit | -5,738,183 | -9,366,943 | -4,064,000 | -8,401,000 | -11,403,000 | -15,037,000 | -2,210,000 | -1,041,000 | -7,334,000 | -6,791,000 | -9,487,000 | -11,129,000 | -5,614,000 | -5,008,000 | -3,703,000 |
| Depreciation | 366,000 | 289,000 | 304,000 | 320,000 | 230,000 | 98,000 | 30,000 | 31,000 | |||||||
| Amortisation | |||||||||||||||
| Tax | -40,000 | -41,000 | |||||||||||||
| Stock | -246,000 | 246,000 | |||||||||||||
| Debtors | 8,440 | -3,000 | 1,000 | -1,000 | 3,000 | -936,000 | 111,000 | 97,000 | 378,000 | 18,000 | 45,000 | 97,000 | -260,000 | 450,000 | |
| Creditors | -404,000 | 150,000 | 19,000 | -78,000 | -64,000 | -8,000 | 188,000 | 92,000 | 105,000 | ||||||
| Accruals and Deferred Income | 30,693 | 105,068 | -49,000 | 106,000 | -878,000 | 822,000 | -1,513,000 | 739,000 | -367,000 | -2,970,000 | -267,000 | -769,000 | 1,689,000 | 2,800,000 | 743,000 |
| Deferred Taxes & Provisions | |||||||||||||||
| Cash flow from operations | -5,715,930 | -9,261,875 | -4,110,000 | -8,296,000 | -12,280,000 | -14,218,000 | -183,000 | -7,531,000 | -9,913,000 | -9,516,000 | -11,721,000 | -3,736,000 | -1,826,000 | -3,274,000 | |
| Investing Activities | |||||||||||||||
| capital expenditure | |||||||||||||||
| Change in Investments | |||||||||||||||
| cash flow from investments | |||||||||||||||
| Financing Activities | |||||||||||||||
| Bank loans | -12,000 | 6,000 | 6,000 | ||||||||||||
| Group/Directors Accounts | |||||||||||||||
| Other Short Term Loans | |||||||||||||||
| Long term loans | -13,996,000 | 7,604,000 | 6,392,000 | ||||||||||||
| Hire Purchase and Lease Commitments | |||||||||||||||
| other long term liabilities | -262,000 | 262,000 | |||||||||||||
| share issue | |||||||||||||||
| interest | 37,000 | 53,000 | 36,000 | 19,000 | 524,000 | 476,000 | 247,000 | 174,000 | 25,000 | 3,000 | 8,000 | 1,000 | |||
| cash flow from financing | 6,523,174 | 7,878,472 | 5,943,000 | 10,932,000 | 14,525,000 | 11,804,000 | -14,172,000 | 8,829,000 | 11,562,000 | 9,603,000 | 12,257,000 | 14,066,000 | 6,667,000 | 1,543,000 | 6,257,000 |
| cash and cash equivalents | |||||||||||||||
| cash | 807,244 | -1,383,404 | 921,000 | 2,087,000 | 280,000 | 395,000 | -11,046,000 | 3,534,000 | 741,000 | -893,000 | 2,434,000 | 1,848,000 | 999,000 | -337,000 | 2,803,000 |
| overdraft | |||||||||||||||
| change in cash | 807,244 | -1,383,404 | 921,000 | 2,087,000 | 280,000 | 395,000 | -11,046,000 | 3,534,000 | 741,000 | -893,000 | 2,434,000 | 1,848,000 | 999,000 | -337,000 | 2,803,000 |
futuragene limited Credit Report and Business Information
Futuragene Limited Competitor Analysis
Perform a competitor analysis for futuragene limited by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other mature companies, companies in EC2V area or any other competitors across 12 key performance metrics.
futuragene limited Ownership
FUTURAGENE LIMITED group structure
Futuragene Limited has no subsidiary companies.
Ultimate parent company
SUZANO TRADING LTD
#0025778
1 parent
FUTURAGENE LIMITED
04001406
futuragene limited directors
Futuragene Limited currently has 3 directors. The longest serving directors include Dr Stanley Hirsch (Aug 2007) and Mr John Corre (Oct 2010).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Dr Stanley Hirsch | Israel | 67 years | Aug 2007 | - | Director |
| Mr John Corre | England | 80 years | Oct 2010 | - | Director |
| Mr Joao De Abreu | Brazil | 55 years | Jul 2024 | - | Director |
P&L
December 2023turnover
0
0%
operating profit
-5.7m
-39%
gross margin
0%
0%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2023net assets
3m
+0.36%
total assets
3.2m
+0.34%
cash
3.2m
+0.34%
net assets
Total assets minus all liabilities
futuragene limited company details
company number
04001406
Type
Private limited with Share Capital
industry
72110 - Research and experimental development on biotechnology
incorporation date
May 2000
age
25
incorporated
UK
ultimate parent company
accounts
Full Accounts
last accounts submitted
December 2023
previous names
futuragene plc (July 2010)
overnet data plc (June 2004)
accountant
-
auditor
CLA EVELYN PARTNERS LIMITED
address
45 45 gresham strret, london, EC2V 7BG
Bank
-
Legal Advisor
FOX WILLIAMS LLP
futuragene limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to futuragene limited.
futuragene limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for FUTURAGENE LIMITED. This can take several minutes, an email will notify you when this has completed.
futuragene limited Companies House Filings - See Documents
| date | description | view/download |
|---|
